32. A composition of an improved anti-IgE antibody or IgE binding fragment in combination with an adjunct immunosuppressive agent, wherein the improved anti-IgE antibody or IgE binding fragment has at least one replaced aspartyl residue prone to isomerization replaced and wherein said improved anti-IgE antibody or IgE binding fragment has at least the same or greater affinity for IgE than the corresponding unimproved antibody or IgE binding fragment.

- 33. The composition of Claim 32 wherein the immunosuppressive agent is selected from the group consisting of 2-amino-5-aryl-substituted pyrimidines, azathioprine, cyclophosphamide, bromocryptine and glutaraldehyde.
- 34. The composition of Claim 32 wherein the immunosuppressive agent is selected from the group consisting anti-idiotypic antibodies which bind MHC antigens or fragments, cyclosporin A, glucocorticosteroids, cytokine antagonists and cytokine receptor antagonists.
- 35. The composition of Claim 32 wherein the immunosuppressive agent is an antibody selected from the group consisting of: anti-tumor necrosis factor-α; anti-tumor necrosis factor-β;anti-interleukin-2; antibodies; anti-L3T4; anti-lymphocyte globulin; anti-CD3; anti-CD4 and anti-CD4a.
- 36. The composition of Claim 32 wherein the immunosuppressive agent is an antibody selected from the group consisting of: a soluble peptide containing a LFA-3 binding domain; streptokinase; TGF-β; streptodornase; deoxyspergualin; rapamycin, T-cell receptor and T cell receptor antibodies.
- 37. The composition of Claim 32 wherein the improved anti-IgE antibody comprises the heavy and light chain sequences of e26 (SEQ ID NO:15/16).
- 38. The composition of Claim 32 wherein the improved IgE binding fragment comprises an E26 sequence selected from the group consisting of: an Fab fragment (SEQ ID NO:19-20; an sFv fragment (SEQ ID NO:22) and an F(ab'), fragment (SEQ ID NO: 24-25).